US2003181388A1PendingUtilityA1
Substituted 2-aminobenzamide caspase inhibitors and the use thereof
Est. expiryMar 16, 2019(expired)· nominal 20-yr term from priority
A61P 39/00A61P 9/00A61P 7/00A61P 43/00A61P 37/00A61P 3/10A61P 7/06A61P 29/00A61P 25/00A61P 25/32A61P 27/02C07D 333/38C07C 2601/14C07C 271/22C07C 271/24A61P 13/12A61P 17/02A61P 19/02A61P 17/14A61P 1/18A61P 17/06A61P 1/02A61P 17/00A61P 15/08C07C 2601/08C07C 271/28A61P 1/04A61P 13/10A61P 1/16A61P 17/16A61P 19/08A61P 1/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to novel 2-aminobenzamide thereof, represented by the general Formula I: where R 1 -R 3 , X, and A-D are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound having the Formulae I or II or III:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R 1 is an optionally substituted alkyl or hydrogen;
R 3 is an N-protecting group;
R 2 is hydrogen or optionally substituted alkyl;
Q is an optionally substituted saturated or partially saturated carbocycle or heterocycle;
X is a peptide of 1-4 amino acids or a bond;
Y is a peptide of 1-4 amino acids or a bond;
A is CR 6 or nitrogen;
B is CR 7 or nitrogen;
C is CR 8 or nitrogen;
D is CR 9 or nitrogen;
provided that not more than two of A, B, C or D is nitrogen; and R 6 -R 9 independently are hydrogen, halo, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, C 4 -C 7 cycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl(C 1 -C 6 )alkyl, C 6 -C 10 aryl(C 2 -C 6 )alkenyl, C 6 -C 10 aryl(C 2 -C 6 )alkynyl, C 1 -C 6 hydroxyalkyl, nitro, amino, cyano, C 1 -C 6 acylamino, hydroxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy, alkylthio, or carboxy; or
one of R 6 and R 7 , or R 7 and R 8 , or R 8 and R 9 are taken together with the carbon atoms to which they are attached to form a carbocycle or heterocycle;
E is C 14 , nitrogen, oxygen or sulfur;
F is C 15 , nitrogen, oxygen or sulfur;
G is C 16 , nitrogen, oxygen or sulfur;
provided that only one of E, F, G is nitrogen, oxygen or sulfur and R 14 -R 16 are independently hydrogen, halo, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, C 4 -C 7 cycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl(C 1 -C 6 )alkyl, C 6 -C 10 aryl(C 2 -C 6 )alkenyl, C 6 -C 10 aryl(C 2 -C 6 )alkynyl, C 1 -C 6 hydroxyalkyl, nitro, amino, cyano, C 1 -C 6 acylamino, hydroxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy, alkylthio, or carboxy; or
one of R 14 and R 15 , or R 15 and R 16 , are taken together with the carbon atoms to which they are attached to form a carbocycle or heterocycle.
2 . A compound according to claim 1 , wherein R 3 is t-butyloxycarbonyl, acetyl or benzyloxycarbonyl.
3 . A compound according to claim 1 , wherein R 1 is H, Me, Et or acetoxymethyl.
4 . A compound according to claim 1 , wherein R 2 is hydrogen, fluoromethyl, acyloxymethyl, arylacyloxymethyl or aminomethyl.
5 . A compound according to claim 1 , wherein X is a bond.
6 . A compound according to claim 1 , wherein A, B, C and D are CH.
7 . A compound according to claim 1 , wherein A is nitrogen, and B, C and D are CH.
8 . A compound according to claim 1 , wherein G is sulfur, and E and F are CH.
9 . A compound according to claim 1 , wherein Q is cyclohexyl or cyclopentyl.
10 . A compound according to claim 1 , wherein said compound has the Formula IV:
or a pharmaceutically acceptable salt or prodrug thereof, wherein
R 2 is hydrogen or optionally substituted alkyl, wherein the substituent is halo, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, amino, acyloxy, or arylacyloxy;
R 6 -R 9 independently are hydrogen, halo, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, C 4 -C 7 cycloalkyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl(C 1 -C 6 )alkyl, C 6 -C 10 aryl(C 2 -C 6 )alkenyl, C 6 -C 10 aryl(C 2 -C 6 )alkynyl, C 1 -C 6 hydroxyalkyl, nitro, amino, cyano, C 1 -C 6 acylamino, hydroxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy, alkylthio, or carboxy; or
one of R 6 and R 7 , or R 7 and R 8 , or R 8 and R 9 are taken together with the carbon atoms to which they are attached to form a carbocycle or heterocycle, selected from the group consisting of —OCH 2 O—, —OCF 2 O—, —(CH 2 ) 3 —, —(CH 2 ) 4 —, —OCH 2 CH 2 O—, —CH 2 N(R 13 )CH 2 —, —CH 2 CH 2 N(R 13 )CH 2 —, —CH 2 N(R 13 )CH 2 CH 2 — and —CH═CH—CH═CH—; wherein R 13 is hydrogen, alkyl or cycloalkyl;
R 10 is hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, C 4 -C 7 cycloalkyl, C 6 -C 10 aryl(C 1 -C 6 )alkyl, benzyloxy, substituted benzyloxy, or NR 11 R 12 ; wherein R 11 and R 12 independently are hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, C 4 -C 7 cycloalkyl, C 6 -C 10 aryl(C 1 -C 6 )alkyl, or R 11 and R 12 are combined to form a heterocyclic ring system selected from the group consisting of pyrrolidine, piperidine, piperazine, and morpholine.
11 . A compound according to claim 10 , wherein R 2 is hydrogen, fluoromethyl, acyloxymethyl, arylacyloxymethyl or aminomethyl.
12 . A compound according to claim 10 , wherein R 10 is benzyloxy.
13 . A compound according to claim 10 , wherein R 1 is H, Me or acetoxymethyl.
14 . A compound according to claim 10 , wherein X is a peptide of 1-2 amino acids or a bond.
15 . A compound according to claim 1 , wherein said compound is selected from the group consisting of:
2-(Z-amino)benzoyl-Asp-fmk, 2-(Z-amino)-3-methylbenzoyl-Asp-fmk, 2-(Z-amino)-3,5-dimethylbenzoyl-Asp-fmk, 2-(Z-amino)-4-chlorobenzoyl-Asp-fmk, 2-(Z-amino)-5-chlorobenzoyl-Asp-fmk, 2-(Z-amino)-5-fluorobenzoyl-Asp-fmk, 2-(Z-amino)-6-fluorobenzoyl-Asp-fmk, cis-2-(Z-amino)-cyclohexanecarboxy-Asp-fmk, 2-(Z-amino)-5-methylbenzoyl-Asp-fmk, 2-(Z-amino)-6-methylbenzoyl-Asp-fmk, 2-(Z-amino)-6-chlorobenzoyl-Asp-fmk, 2-(Z-amino)-3-methoxybenzoyl-Asp-fmk, 3-(Z-amino)thiophene-2-carboxyl-Asp-fmk, 3-(methoxycarbonylamino)thiophene-2-carboxyl-Asp-fmk, cis-2-(Z-amino)cyclopentanecarboxyl-Asp-fmk, trans-2-(Z-amino)cyclopentanecarboxyl-Asp-fmk, 2-(Z-amino)benzoyl-Asp-DCB-methylketone, methoxycarbonyl-Val-(2-aminobenzoyl)-Asp-fmk, Z-Glu-(2-aminobenzoyl)-Asp-fmk, and Z-Val-(2-aminobenzoyl)-Asp-fmk.
16 . A pharmaceutical composition, comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
17 . A method of inhibiting cell death of a cell or tissue, comprising contacting said cell or tissue with an effective amount of a compound of claim 1 .
18 . A method of treating or ameliorating cell death in the central or peripheral nervous system, retinal neurons, cardiac muscle or immune system cells of an animal, comprising administering to the animal in need of such treatment or ameliorating an effective amount of a compound of claim 1 .
19 . The method of claim 18 , wherein said cell death is in the central or peripheral nervous system, and is due to one of:
(a) a condition of ischemia and excitotoxicity selected from the group consisting of focal ischemia due to stroke and global ischemia due to cardiac arrest; (b) traumatic injury; (c) viral infection; (d) radiation-induced nerve cell death; (e) a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, Parkinson's Disease, a prion disease, multiple sclerosis, amyotrophic lateral sclerosis, and spinobulbar atrophy; (f) spinal cord injury; or (g) acute bacterial meningitis.
20 . The method of claim 18 , wherein said cell death is in the central or peripheral nervous system, and is due to expansion of trinucleotide repeats of specific genes.
21 . The method of claim 18 , wherein said cell death is due to Huntington's Disease.
22 . The method of claim 18 , wherein said cell death is in cardiac muscle tissue, and is due to myocardial infarction, congestive heart failure, cardiomyopathy or viral infection of the heart.
23 . The method of claim 18 , wherein said cell death is in retinal neurons and is due to increased intraocular pressure, age-related macular degeneration or retinitis pigmentosa.
24 . The method of claim 18 , wherein said cell death is in the immune system, and is due to an immune deficiency disorder selected from the group consisting of acquired immune deficiency syndrome, severe combined immune deficiency syndrome and radiation-induced immune suppression.
25 . The method of claim 18 , wherein said cell death is due to an autoimmune disorder selected from the group consisting of lupus erythematosus, rheumatoid arthritis and type I diabetes.
26 . The method of claim 18 , wherein said cell death is due to type I diabetes.
27 . A method of treating or preventing polycystic kidney disease, renal amyloidosis, acute renal failure, cyclosporine A induced tubular epithelial cell death, hypoxia-induced necrosis of renal proximal tubules, HIV-induced nephropathy or anemia/erythropoiesis in an animal, comprising administering to the animal in need of such treatment an effective amount of a compound of claim 1 .
28 . A method of protecting a mammalian organ or tissue from cell death due to deprivation of normal blood supply, comprising contacting said organ or tissue with an effective amount of a compound of claim 1 .
29 . The method of claim 28 , wherein said organ or tissue is present in a storage medium prior to transplant into a mammal.
30 . The method of claim 28 , wherein said contacting comprises infusion of said compound into the organ or tissue, or bathing of said organ or tissue in a storage medium which comprises said compound.
31 . A method of reducing or preventing cell death in a donor organ or tissue after it has been transplanted into a host due to the effects of reperfusion injury or due to the effects of host immune cells, comprising administering to said host in need thereof an effective amount of a compound of claim 1 .
32 . A method of reducing or preventing the death of mammalian sperm or eggs used in in vitro fertilization procedures, comprising contacting said sperm or egg with an effective amount of a compound of claim 1 .
33 . A method of extending the lifespan of a mammalian or yeast cell line, comprising contacting said cell line with a compound of claim 1 .
34 . The method of claim 33 , wherein said contacting comprises including said compound in a cell growth medium.
35 . A method of treating or ameliorating hair loss or premature graying of the hair in a mammal, comprising contacting the hair or hair follicles of the mammal in need thereof with a compound of claim 1 .
36 . The method of claim 35 , wherein hair loss is treated, and said hair loss is due to male-pattern baldness, radiation, chemotherapy or emotional stress.
37 . A method of treating or ameliorating skin damage of a mammal due to exposure to high levels of radiation, heat or chemicals, comprising applying to the skin of the mammal in need thereof with a compound of claim 1 .
38 . The method of claim 37 , wherein said compound is applied as part of an ointment.
39 . The method of claim 37 , wherein said skin damage is due to acute over-exposure to the sun, and wherein said treating reduces blistering and peeling of the skin.
40 . A method of treating or ameliorating sepsis or multi-organ failure in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
41 . A method of treating or ameliorating hepatitis in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
42 . A method of treating or ameliorating hereditary tyrosinemia type 1 in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
43 . A method of treating or ameliorating chronic alcohol ingestion induced buccal mucosa cell death in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
44 . A method of treating or ameliorating cell death in plants or flowers, comprising administering to the plants or flowers in need thereof an effective amount of a compound of claim 1 .
45 . A method of treating or ameliorating radiation or ultraviolet-irradiation induced cell death in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
46 . A method of treating or ameliorating apoptotic death of bone marrow cells in myelodysplastic syndromes (MDS), comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
47 . A method of treating or ameliorating apoptotic cell death in acute pancreatitis, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
48 . A method of treating or preventing the inflammatory response in psoriasis or inflammatory bowel disease, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
49 . A method of treating or ameliorating organ apoptosis after burn injury, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
50 . A method of treating or ameliorating small bowel tissue injury after intestinal ischemia-reperfusion, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
51 . A method of treating, ameliorating or preventing oral mucositis, gastrointestinal mucositis, bladder mucositis, proctitis, bone marrow cell death, skin cell death or hair loss resulting from chemotherapy or radiation therapy of cancer in an animal, comprising administering to the animal in need thereof an effective amount of a compound of claim 1 .
52 . The method of claim 51 , wherein said compound is administered topically or orally.
53 . The method of claim 52 , wherein said compound is formulated as part of a mouthwash for the treatment, amelioration or prevention of oral mucositis.
54 . The method of claim 52 , wherein said compound is formulated as part of a slow release buccal lozenge.
55 . The method of claim 52 , wherein said compound is formulated as part of a suppository.
56 . The method of claim 52 , wherein said compound is formulated as part of a gel.
57 . The method of claim 52 , wherein said compound is administered through a bladder catheter for the treatment, amelioration or prevention of bladder mucositis.
58 . The method of claim 52 , wherein said compound is administered as part of an enema for the treatment, amelioration or prevention of proctitis.
59 . The method of claim 52 , wherein said compound is formulated as an oral formulation which is capable of coating the gastrointestinal surfaces for the treatment, amelioration or prevention of gastrointestinal mucositis.
60 . The method of claim 59 , wherein said gastrointestinal mucositis is esophageal mucositis, gastric mucositis, or intestinal mucositis.
61 . The method of claim 51 , wherein said compound is administered by i.v. injection for the treatment, amelioration or prevention of bone marrow cell death.
62 . The method of claim 51 , wherein said compound is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
63 . The method of claim 51 , wherein said compound is administered after chemotherapy or radiation therapy of cancer in said animal.
64 . The method of claim 51 , wherein said compound is administered during chemotherapy or radiation therapy of cancer in said animal.
65 . The method of claim 51 , wherein said compound is administered prior to chemotherapy or radiation therapy of cancer in said animal.Join the waitlist — get patent alerts
Track US2003181388A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.